UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Canaccord Genuity’s 44^th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Merus to Present at Upcoming Investor Conferences

Merus to Participate in Upcoming Investor Conferences

Merus to Participate in Upcoming Investor Conferences

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Merus N.V. Announces Proposed Public Offering of Common Shares

Merus Announces Pricing of Upsized Public Offering of Common Shares